arrow
S

Sabine Blum

university oflausanne
H指数:24
被引数:2,055

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASE

比较治疗相关和原发性MDS的1590例与4738例患者预后变量和细胞遗传学异常的比较,包括MDS阶段治疗的影响

2025-09-010
PRE
Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
2024-03-070
OAAI
The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification
LEUKEMIA
IF13.4
2024-01-234
OAAI
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
2023-06-193
OAAI
MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology
2023-04-016
OAAI
Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript

Daratumumab和venetoclax联合化疗可在复发/难治性CD19,CD20和CD22阴性的急性B淋巴细胞白血病中提供持续的分子缓解,并具有KMT2A-AFF1转录本

2021-12-209
OAAI